Reflecting on NMIBC Progress: Highlights From AUA 2025 and What’s Ahead

EP: 1.Assessing Risk in NMIBC: A Foundation for Therapy

EP: 2.From Papillary to CIS: Tailoring NMIBC Treatment

EP: 3.Defining and Managing BCG-Unresponsive NMIBC

EP: 4.NMIBC Maintenance Therapy: Timing, Dosing, and Follow-Up

EP: 5.FDA-Approved Options for High-Risk BCG-Unresponsive NMIBC

EP: 6.An Overview Of Pembrolizumab for High-Risk BCG Unresponsive NMIBC

EP: 7.An Overview of Nogapendekin Alfa Inbakicept for High-Risk, BCG-Unresponsive NMIBC

EP: 8.Real-World Outcomes With Nadofaragene in BCG-Unresponsive NMIBC

EP: 9.Exploring Nadofaragene Firadenovec: Ongoing Trials and Study Designs

EP: 10.Topline Results From Recent NMIBC Trials

EP: 11.Overcoming Challenges in Accessing New Therapies for NMIBC

EP: 12.Navigating Access Barriers: Resources to Support New Treatment Access

Now Viewing

EP: 13.Reflecting on NMIBC Progress: Highlights From AUA 2025 and What’s Ahead

Physician Summary: Reflections on Progress and Looking Ahead in NMIBC – AUA 2025

As we reflect on the progress made in the treatment of non–muscle-invasive bladder cancer (NMIBC) leading up to AUA 2025, several key accomplishments and developments stand out:

1. Pivotal Accomplishments in NMIBC:

• The approval and integration of nadofaragene firadenovec and pembrolizumab into treatment options for BCG-unresponsive NMIBC have been major milestones. These therapies are reshaping how we approach treatment in this difficult-to-manage patient population.

• The advances in intravesical therapies such as TAR-200, UGN-102, and UGN-103 have significantly improved patient convenience, offering sustained release options that reduce treatment burden and improve patient adherence.

• Immunotherapy has emerged as a transformative approach, with KEYNOTE-057 and CORE-001 trials presenting exciting data, demonstrating the potential for combination therapies and the synergy between oncolytic viruses and PD-1 inhibitors.

1. Exciting Developments at AUA 2025:

• The new data presented at AUA 2025 highlight the promising long-term efficacy and safety of emerging therapies, including further insights from ongoing trials like ABLE-32 and ABLE-41, which could potentially expand treatment options for intermediate-risk and real-world NMIBC patients.

• Early-stage data on novel immunotherapies and combination approaches with cretostimogene grenadenorepvec and pembrolizumab suggest the potential for increased response rates and durability of treatment outcomes.

1. Looking Ahead to 2025 and Beyond:

• Opportunities for Significant Progress: We’re on the cusp of potentially groundbreaking developments in biomarker-driven therapies, which will help tailor treatments to individual patients. The expansion of real-world data will also be crucial in refining treatment strategies for NMIBC.

• What I’m Most Excited About: I’m particularly excited about advances in immunotherapy and intravesical delivery systems. The combination of personalized medicine with cutting-edge treatments holds great promise for improving outcomes in NMIBC patients.

• What I Hope to Achieve in 2025: I look forward to seeing broader access to these new treatments and refining our understanding of their long-term durability, safety, and efficacy. I hope to contribute to optimizing patient selection and minimizing treatment-related adverse effects as we advance these therapies into clinical practice.

In the coming year, I believe we’ll continue to see significant strides in NMIBC treatment, and I am excited to be part of the evolution in care that will ultimately lead to better outcomes for our patients.